Evidence for the Antimetastatic Effects of Coumarin Derivatives

  • Peter Hilgard
Part of the Developments in Oncology book series (DION, volume 22)


The first morphological evidence for an association of intravascular cancer cells with thrombotic material was found at the beginning of this century (1). However, not until more than 50 yr later was the possible pathogenic significance of this phenomenon recognized. Observing the fate of intravascular tumor cells in vivo in the Hopkins rabbit ear chamber, Wood (2) found that a tumor cell embolus was rapidly surrounded by microthrombi shortly after its initial attachment to the vascular endothelium. By time-lapse cinematography the investigator was able to document how these intravascular cancer cells, sheltered by their surrounding thrombus, penetrated the vessel wall into the perivascular tissue where they started to proliferate into a “secondary” tumor. From these observations Wood concluded that the activation of the coagulation system at the site of tumor cell lodgment was of significance in the initial phase of the hematogenous spread of malignant tumors.


Lewis Lung Carcinoma Prothrombin Complex Concentrate Coumarin Derivative Spontaneous Metastasis Lewis Lung Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schmidt MB. Die Verbreitungswege der Carcinane und die Beziehung generalisierter Sarkome zu den leukamischen Neubildungen. Fisher, Jena, 1903.Google Scholar
  2. 2.
    Wood S, Jr. Arch. Pathol. 66: 550–568, 1958.Google Scholar
  3. 3.
    Hilgard P. In: The Thromboembolic Disorders (Eds. van de Loo J, Prentice CRM and Beller FK), SchattauerVerlag, Stuttgart, pp. 457–470, 1983.Google Scholar
  4. 4.
    Hilgard P and Thornes RD. Eur. J. Cancer 12: 755–762, 1976.CrossRefGoogle Scholar
  5. 5.
    Maat B and Hilgard P. J. Cancer Res. Clin. Oncol. 101: 275–283, 1981.PubMedCrossRefGoogle Scholar
  6. 6.
    Hilgard P, Schulte H, Wetzig G, Schmitt G and Schmidt OG. Br. J. Cancer 35: 78–85, 1977.PubMedCrossRefGoogle Scholar
  7. 7.
    Thornes RD. Cancer (Philadelphia) 35: 91–97, 1975.CrossRefGoogle Scholar
  8. 8.
    Matis P, Konold P, Mayer W and Liebaldt G. Thromb. Diath. Haemorrh. Suppl. 15: 109–121, 1964.Google Scholar
  9. 9.
    Jindal MN and Shah DS. Arzneim.-Forsch./Drug Res. 16: 878–881, 1966.Google Scholar
  10. 10.
    Fontaine L, Grand M, Quentin Y and Merle S. Mad. Pharmacol. Exp. 13: 137–154, 1965.Google Scholar
  11. 11.
    Goth A. Science 101: 383, 1945.PubMedCrossRefGoogle Scholar
  12. 12.
    Martius C and Nitz-Utzow D. Biochim. Biophys. Acta 12: 134–140, 1953.PubMedCrossRefGoogle Scholar
  13. 13.
    McGirr JL and Papworth DS. Vet. Rec. 67: 124–131, 1955.Google Scholar
  14. 14.
    Higashi H and Heidelberger C. Cancer Chemotherp. Rep. Part I 55: 29–33, 1971.Google Scholar
  15. 15.
    Chang JC and Hall TC. Oncology 28: 232–236, 1973.PubMedCrossRefGoogle Scholar
  16. 16.
    Kirsh WM, Schulz D, van Boskirk JJ and Young HE. J. Med. 5: 69–75, 1974.Google Scholar
  17. 17.
    Thornes RD, Edlow DW and Wood S, Jr. Johns Hopkins Med. J. 123: 305–324, 1968.Google Scholar
  18. 18.
    Hilgard P. In: Malginancy and the Hemostatic Systan (Eds. Donati MB, Dvaidson JF and Garattini S), Raven Press, New York, pp. 103–111, 1981Google Scholar
  19. 19.
    Hoover HD, Jr., Jones D and Ketcham AS. Surgery 879: 625–6730, 1976.Google Scholar
  20. 20.
    Hilgard P and Maat B. Eur. J. Cancer 15: 183–187, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Poggi A, Mussoni L, Kornblihtt L, Ballabio E, de Gaetano G and Donati MB. Lancet 1: 163–164, 1978.PubMedCrossRefGoogle Scholar
  22. 22.
    Hilgard P. Br. J. Cancer 35: 891–892, 1977.PubMedCrossRefGoogle Scholar
  23. 23.
    Stenflo J. J. Biol. Chem. 251: 355–363,1976.PubMedGoogle Scholar
  24. 24.
    Gordon SG, Franks JJ and Lewis B. Thromb. Res. 6: 127–131, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Gordon SG, Franks JJ and Lewis BJ. J. Natl. Cancer Inst. 62: 773–778, 1979.PubMedGoogle Scholar
  26. 26.
    Gordon SG and Cross BA. J. Clin. Invest. 67: 1665–1671, 1981.PubMedCrossRefGoogle Scholar
  27. 27.
    Semeraro N and Donati MB. In: Malignancy and the Hemostatic System (Eds. Donati MB, Davidson JF and Garattini S), Raven Press, New York, pp. 65–81, 1981.Google Scholar
  28. 28.
    Hilgard P and Whur P. Br. J. Cancer 41: 642–643, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Colucci M, Delaini F, de Bellis Vitti G, Locati D, Poggi A, Semeraro N and Donati MB. Biochem. Pharmacol. 32: 1689–1691, 1983.PubMedCrossRefGoogle Scholar
  30. 30.
    Maat B. Br. J. Cancer 41: 313–316, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Peter Hilgard

There are no affiliations available

Personalised recommendations